Condition
Rare Genetic Disease
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (3)
Trial Status
Completed1
Not Yet Recruiting1
Enrolling By Invitation1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06731790Not ApplicableCompletedPrimary
Role of the Nuclear Pore Component RANBP2 in Inflammatory Responses to Viral Infections
NCT05236595Enrolling By InvitationPrimary
Research for Individualized Therapeutics in Rare Genetic Disease
NCT07075107Not ApplicableNot Yet RecruitingPrimary
Transcriptomic Analysis of Fibroblasts and Blood in Patients With Rare Diseases
NCT04406480Not ApplicableUnknown
Realization of Sequencing of All Known Human Genes in Case of Detection of Cerebral, Renal or Ophthalmological Fetal Malformations During Pregnancy in Order to Make an Etiological Diagnosis and to Precise the Fetal Prognosis
Showing all 4 trials